Combining obinutuzumab and lenalidomide for treating relapsed follicular lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the efficacy and safety of obinutuzumab in combination with lenalidomide for patients with relapsed or refractory follicular lymphoma (R/R FL) in a real-world setting in China. It will assess various outcomes including overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), event-free survival (EFS), duration of response (DOR), overall survival (OS), and safety. The study will not involve any changes to the patients' treatment plans, as all interventions will be at the discretion of their physicians. The goal is to verify the previously observed efficacy and safety of this combination specifically in the Chinese patient population.

Why it matters

Who can join: the full rules

Patients must meet the following criteria for study entry::

* Signed Informed Consent Form
* Age ≥ 18 years at enrollment
* At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy
* Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma.
* Conditional treatment with obinutuzumab in combination with lenalidomide

Exclusion Criteria:

* Patients currently participating or planning to participate in any interventional clinical trial
* Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study

Where it's running

• Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
  Tianjin, China Recruiting

Study contacts

• Principal investigator: Shuhua Yi, Dr — Institute of Hematology & Blood Diseases Hospital, Chinese
• Study coordinator: shuhua Yi, Dr
• Email: yishuhua@ihcams.ac.cn
• Phone: 86-22-23909106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• Fixed-duration zanubrutinib plus bendamustine and obinutuzumab for newly diagnosed advanced follicular lymphoma

  This tests a six-cycle combination of zanubrutinib, bendamustine, and obinutuzumab for adults with newly diagnosed advanced-stage follicular lymphoma.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07126678

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• Treatment for high tumor burden follicular lymphoma using obinutuzumab and CC-99282

  This study is testing if a new combination of obinutuzumab and CC-99282 can help people with high tumor burden follicular lymphoma who haven't been treated before feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06108232

• Comparing radiotherapy alone versus with Obinutuzumab for early stage follicular lymphoma

  This study is testing if adding Obinutuzumab to radiation therapy helps people with early-stage follicular lymphoma do better than just radiation alone.

  Recruiting at 43 sites Phase 3 Fondazione Italiana Linfomi - ETS · Sassuolo, Modena (MO) and 48 other locations · NCT05929222

• Observing the effects of obinutuzumab for untreated follicular lymphoma

  This study looks at how well the drug obinutuzumab works and how safe it is for people with untreated follicular lymphoma in real-life settings.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05899621

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.